Free Trial

Avanza Fonder AB Buys New Holdings in Avantor, Inc. (NYSE:AVTR)

Avantor logo with Medical background

Avanza Fonder AB purchased a new position in shares of Avantor, Inc. (NYSE:AVTR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 64,936 shares of the company's stock, valued at approximately $1,368,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its holdings in shares of Avantor by 1.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 1,097,671 shares of the company's stock valued at $23,271,000 after purchasing an additional 18,672 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Avantor by 8.6% in the second quarter. Dimensional Fund Advisors LP now owns 4,434,195 shares of the company's stock valued at $94,018,000 after buying an additional 350,247 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Avantor by 4.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 25,440 shares of the company's stock valued at $539,000 after acquiring an additional 1,119 shares during the last quarter. Seven Eight Capital LP acquired a new position in Avantor during the second quarter worth about $642,000. Finally, First Eagle Investment Management LLC lifted its holdings in shares of Avantor by 16.4% in the second quarter. First Eagle Investment Management LLC now owns 18,482 shares of the company's stock worth $392,000 after acquiring an additional 2,600 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Avantor Trading Down 1.9 %

Avantor stock traded down $0.43 during mid-day trading on Friday, hitting $22.14. 6,042,606 shares of the stock were exchanged, compared to its average volume of 3,101,021. Avantor, Inc. has a 12 month low of $19.59 and a 12 month high of $28.00. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm's fifty day simple moving average is $21.45 and its two-hundred day simple moving average is $23.37. The stock has a market capitalization of $15.07 billion, a price-to-earnings ratio of 48.13, a PEG ratio of 3.42 and a beta of 1.28.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AVTR shares. UBS Group reiterated a "neutral" rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a research report on Friday. Wells Fargo & Company lowered their price target on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Monday, October 28th. Royal Bank of Canada reissued an "outperform" rating and set a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Barclays lowered their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, October 25th. Finally, Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Avantor currently has an average rating of "Moderate Buy" and a consensus target price of $27.38.

Get Our Latest Stock Analysis on Avantor

Avantor Company Profile

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Recommended Stories

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Should You Invest $1,000 in Avantor Right Now?

Before you consider Avantor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.

While Avantor currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines